Prevalence and progression rate of diabetic retinopathy in type 1 diabetes patients in correlation with the duration of diabetes

AIMS We examined prevalence and progression of retinopathy in dependence on diabetes duration in order to estimate the probability of progression. PATIENTS/METHODS In a retrospective cohort-analysis from an academic outpatient department of endocrinology and metabolic diseases we analyzed 17461 consultations of 4513 patients with DM2 from 1987 to 2014. 50.3% of the patients (n=2272) had at least one documented result of funduscopy. RESULTS 25.8% of the patients had retinopathy (20.2% non-proliferative, 4.7% proliferative, 0.7% were not classified, 0.1% blindness). The prevalence of retinopathy in dependence on diabetes duration was 1.1% at diagnosis, 6.6% after 0<5 years, 12% after 5<10 years, 24% after 10<15 years, 39.9% after 15<20 years, 52.7% after 20<25 years, 58.7% after 25<30 years and 63% after ≥30 years. In a subset of 586 (25.7%) patients with retinal photography of 3 consecutive years 7.0% showed deterioration after one and 12.2% after two years; 2.6% improved after one and 2.8% after two years. 201 (34.3%) of this group had<10 years diabetes and lower deterioration (4.5% worsened after one and 9.5% after two years). Their retinopathy mainly transformed from no retinopathy to non-proliferative. Four patients (2.0%) developed proliferative retinopathy. CONCLUSIONS/INTERPRETATIONS Within the first 10 years of diabetes duration, the prevalence of retinopathy is low and the progression infrequent. Most patients have a non-proliferative form which can be reversible and rarely requires interventions. Patients with DM2 without retinopathy and good glycaemic control do not run into additional risk from expanding funduscopy intervals to biennial.

[1]  Grading Diabetic Retinopathy from Stereoscopic Color Fundus Photographs - An Extension of the Modified Airlie House Classification: ETDRS Report Number 10. , 2020, Ophthalmology.

[2]  H. Hammes,et al.  Risk Factors for Retinopathy and DME in Type 2 Diabetes—Results from the German/Austrian DPV Database , 2015, PloS one.

[3]  N. Müller,et al.  Healthcare utilization of people with Type 2 diabetes in Germany: an analysis based on health insurance data , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[4]  T. Peto,et al.  Correction: Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study , 2015, PloS one.

[5]  T. Peto,et al.  Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study , 2015, PloS one.

[6]  T. Sundt,et al.  Process versus outcome: the sugar window. , 2014, The Journal of thoracic and cardiovascular surgery.

[7]  T. Sundt,et al.  Process versus outcome: The sugar window. , 2014, The Journal of thoracic and cardiovascular surgery.

[8]  Max O Bachmann,et al.  Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England. Diabetes Care 2012;35:592–596 , 2014, Diabetes Care.

[9]  Clinical characteristics influence screening intervals for diabetic retinopathy , 2013, Diabetologia.

[10]  J. Olson,et al.  Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme , 2013, Diabetologia.

[11]  Allan Vaag,et al.  Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus , 2011, The Cochrane database of systematic reviews.

[12]  Toke Bek,et al.  Individualized optimization of the screening interval for diabetic retinopathy: a new model , 2012, Acta ophthalmologica.

[13]  R V North,et al.  Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis , 2012, BMJ : British Medical Journal.

[14]  B. Klein,et al.  Global Prevalence and Major Risk Factors of Diabetic Retinopathy , 2012, Diabetes Care.

[15]  M. Bachmann,et al.  Incidence and Progression of Diabetic Retinopathy During 17 Years of a Population-Based Screening Program in England , 2012, Diabetes Care.

[16]  B. Hemmingsen Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus , 2011, The Cochrane database of systematic reviews.

[17]  E. Stefánsson,et al.  Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy , 2011, Diabetologia.

[18]  E. Agardh,et al.  Adopting 3-Year Screening Intervals for Sight-Threatening Retinal Vascular Lesions in Type 2 Diabetic Subjects Without Retinopathy , 2011, Diabetes Care.

[19]  N. Müller,et al.  Better HbA1c and blood pressure control in patients with diabetes mellitus treated at a primary health care level 10 years after initiation of a diabetes quality improvement program. , 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[20]  L. Welschen,et al.  Progression and Regression: Distinct Developmental Patterns of Diabetic Retinopathy in Patients With Type 2 Diabetes Treated in the Diabetes Care System West-Friesland, the Netherlands , 2011, Diabetes Care.

[21]  Ann L. Albright,et al.  Prevalence of diabetic retinopathy in the United States, 2005-2008. , 2010, JAMA.

[22]  R. Klein,et al.  Are Individuals With Diabetes Seeing Better? , 2010, Diabetes.

[23]  Tien Yin Wong,et al.  Diabetic retinopathy , 2010, The Lancet.

[24]  M. Ulbig,et al.  Diabetic retinopathy: Early diagnosis and effective treatment. , 2010, Deutsches Arzteblatt international.

[25]  D. Whiting,et al.  The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. , 2010, Diabetes research and clinical practice.

[26]  E. Stefánsson,et al.  Biennial eye screening in patients with diabetes without retinopathy: 10-year experience , 2007, British Journal of Ophthalmology.

[27]  U. Müller,et al.  Prävalenz der diabetischen Retinopathie , 2007, Der Ophthalmologe.

[28]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[29]  Simon P Harding,et al.  Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study , 2003, The Lancet.

[30]  B. Jönsson,et al.  Revealing the cost of Type II diabetes in Europe , 2002, Diabetologia.

[31]  P. Hartmann,et al.  Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg , 2001, Der Ophthalmologe.

[32]  R. Hayward,et al.  Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. , 2000, JAMA.

[33]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[34]  M. Bachmann,et al.  Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. , 1998, Journal of epidemiology and community health.

[35]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.